Medscape23h
Cabozantinib Improves PFS in Advanced Neuroendocrine Tumors After Prior Treatment
Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.
Oncology Nurse Advisor17d
Radioembolization Plus Chemo Shows Activity in Liver-Dominant Metastatic NETs
The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.
ascopubs.org18d
Adjuvant therapy with somatostatin analogs for recurrent gastric neuroendocrine tumors type 1.
Matching adjusted indirect comparison (MAIC) of 177Lu-DOTATATE vs. sunitinib as first-line (1L) treatment for advanced grade 2 (G2) pancreatic neuroendocrine tumors (pNETs). This is an ASCO Meeting ...
Business Wire20d
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO ...
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...
C&EN24d
Preparation, Antifungal Activity Evaluation, and Mechanistic Studies of Unique and Structurally Novel Pyrazole-Heterocyclic-Amide Analogues
School of Science, Asymmetric Synthesis and Chirotechnology Key Laboratory of Sichuan Province, Xihua University, Chengdu 610039, P. R. China ...
MusicRadar28d
NAMM 2025: Offering both digital and analogue control, Flock Audio’s Switch takes takes audio routing to the next level
After the arrival of Heritage Audio’s Synth Buddy and hot on the heels of Franklin Audio’s SS-6 MKII Switchable Input Stereo DI, Flock Audio has just announced Switch, an analogue instrument routing ...